Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
LB Pharmaceuticals will host an in-person and virtual R&D Day on Oct. 27, 2026, at 2 p.m. ET, highlighting its LB-102 schizophrenia program. A planned topline Phase 3 readout for LB-102 in schizophrenia is expected in H1 2027.
LB Pharmaceuticals Inc. announced it will host an in-person and virtual R&D Day on October 27, 2026, to discuss advancements in LB-102, a treatment for schizophrenia.